Table 1.
Demographics of the pneumococcal dataset in this study
|
Characteristics |
Percentage (n/N) |
||
|---|---|---|---|
|
Agincourt |
Soweto |
Total |
|
|
n |
1097 |
728 |
1825 |
|
Gender |
|||
|
Female |
50.3 % (552/1097) |
58.8 % (426/725) |
53.7 % (978/1822) |
|
Male |
49.7 % (545/1097) |
41.2 % (299/725) |
46.3 % (844/1822) |
|
Age groups (year) |
|||
|
≤2 |
57.8 % (634/1097) |
49.6 % (361/728) |
54.5 % (995/1825) |
|
3–5 |
18.2 % (200/1097) |
26.1 % (190/728) |
21.37 % (390/1825) |
|
>5 |
24 % (263/1097) |
24.3 % (177/728) |
24.1 % (440/1825) |
|
HIV status |
|||
|
HIV-infected |
93.2 % (357/383) |
50.1 % (364/727) |
64.9 % (721/1110) |
|
HIV-uninfected |
6.8 % (26/383) |
49.9 % (363/727) |
35.1 % (389/1110) |
|
Year |
|||
|
2009 |
34.1 % (374/1097) |
– |
20.5 % (374/1825) |
|
2010 |
– |
49.5 % (360/728) |
19.7 % (360/1825) |
|
2011 |
32.6 % (358/1097) |
– |
19.6 % (358/1825) |
|
2012 |
– |
47.5 % (346/728) |
19.0 % (346/1825) |
|
2013 |
33.27 % (365/1097) |
3.0 % (22/728) |
21.2 % (387/1825) |
|
Vaccine era |
|||
|
PCV7 |
49.1 % (539/1097) |
49.5 % (360/728) |
49.2 % (899/1825) |
|
PCV13 |
50.9 % (558/1097) |
50.5 % (368/728) |
50.8 % (926/1825) |
Samples were grouped into two vaccine periods based on the date of sample collection: (1) PCV7 era: included samples collected between June 2009 and July 2011 (after the introduction of PCV7 but before PCV13), (2) PCV13 era: included samples collected between August 2011 and November 2013 (after the introduction of PCV13).